RT Journal Article
T1 Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
A1 Díaz-Rubio, Eduardo
A1 Gómez-España, Auxiliadora
A1 Massutí, Bartomeu
A1 Sastre, Javier
A1 Reboredo, Margarita
A1 Manzano, José Luis
A1 Rivera, Fernando
A1 Safont, M José
A1 Montagut, Clara
A1 González, Encarnación
A1 Benavides, Manuel
A1 Marcuello, Eugenio
A1 Cervantes, Andrés
A1 Martínez de Prado, Purificación
A1 Fernández-Martos, Carlos
A1 Arrivi, Antonio
A1 Bando, Inmaculada
A1 Aranda, Enrique
K1 Neoplasias colorrectales
K1 Desoxicitidina
K1 Fluorouracilo
K1 Mutación
K1 Metástasis neoplásica
K1 Pronóstico
K1 Protocolos de quimioterapia antineoplásica combinada
AB BACKGROUNDIn the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An additional retrospective analysis was performed to define the prognostic value of tumour KRAS status on progression-free survival (PFS), overall survival (OS) and response rates.METHODOLOGY/PRINCIPAL FINDINGSKRAS data (tumour KRAS status and type of mutation) were collected by questionnaire from participating centres that performed KRAS analyses. These data were then cross-referenced with efficacy data for relevant patients in the MACRO study database. KRAS status was analysed in 394 of the 480 patients (82.1%) in the MACRO study. Wild-type (WT) KRAS tumours were found in 219 patients (56%) and mutant (MT) KRAS in 175 patients (44%). Median PFS was 10.9 months for patients with WT KRAS and 9.4 months for patients with MT KRAS tumours (p=0.0038; HR: 1.40; 95% CI:1.12-1.77). The difference in OS was also significant: 26.7 months versus 18.0 months for WT versus MT KRAS, respectively (p=0.0002; HR: 1.55; 95% CI: 1.23-1.96). Univariate and multivariate analyses showed that KRAS was an independent variable for both PFS and OS. Responses were observed in 126 patients (57.5%) with WT KRAS tumours and 76 patients (43.4%) with MT KRAS tumours (p=0.0054; OR: 1.77; 95% CI: 1.18-2.64).CONCLUSIONS/SIGNIFICANCEThis analysis of the MACRO study suggests a prognostic role for tumour KRAS status in patients with mCRC treated with XELOX plus bevacizumab. For both PFS and OS, KRAS status was an independent factor in univariate and multivariate analyses.
PB Public Library of Science
YR 2012
FD 2012-10-12
LK http://hdl.handle.net/10668/1333
UL http://hdl.handle.net/10668/1333
LA en
NO Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, et al. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study. PLoS ONE. 2012; 7(10):e47345
NO Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 7, 2025